The Department of Internal Medicine is grateful to have received a generous philanthropic gift of $100,000 to speed initiation of phase II clinical trials of sobetirome, a well-characterized thyromimetic drug, as an early treatment for COVID-19. Naftali Kaminski, MD, Chief of Pulmonary, Critical Care and Sleep Medicine Section and Professor of Medicine, and his team are pursuing this treatment approach—one that aims to address the lung injury component of COVID-19-induced acute respiratory distress syndrome (ARDS) to halt disease progression. Kaminski’s team believes that sobetirome will enhance lung resilience to injury in COVID-19-induced ARDS and accelerate recovery from COVID-19 and is in communication with FDA about starting a trial soon.
If you are interested in making a gift to support COVID-19 or other research within YSM’s Department of Internal Medicine, please contact Erin Shreve in the Office of Development at (203) 465-2458 or erin.shreve@yale.edu.